199 related articles for article (PubMed ID: 19246419)
21. Aromatase inhibitors: what is the true cost?
Houston KE; Thomson DB
Intern Med J; 2011 Feb; 41(2):139-40. PubMed ID: 22747552
[No Abstract] [Full Text] [Related]
22. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
Grana G
J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
[TBL] [Abstract][Full Text] [Related]
23. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
Sanz A; Del Valle ML
N Engl J Med; 2016 Oct; 375(16):1590. PubMed ID: 27797309
[No Abstract] [Full Text] [Related]
24. Extending Adjuvant Aromatase-Inhibitor Therapy to 10 Years.
Ingle JN; Parulekar WR
N Engl J Med; 2016 Oct; 375(16):1591. PubMed ID: 27797308
[No Abstract] [Full Text] [Related]
25. Postmenopausal breast cancer: a best endocrine strategy?
Mayer EL; Burstein HJ
Lancet; 2015 Oct; 386(10001):1317-1319. PubMed ID: 26211823
[No Abstract] [Full Text] [Related]
26. Adjuvant endocrine therapy for breast cancer: a commentary.
Pritchard KI; Ruste AS
Oncology (Williston Park); 2012 Jun; 26(6):568, 570. PubMed ID: 22870541
[No Abstract] [Full Text] [Related]
27. Tamoxifen in breast cancer: not so easy to write off.
Munshi A; Singh P
Breast; 2008 Apr; 17(2):121-4. PubMed ID: 17923407
[TBL] [Abstract][Full Text] [Related]
28. Exemestane or tamoxifen?
Atkins CD
Lancet; 2007 May; 369(9573):1600; author reply 1600-1. PubMed ID: 17499597
[No Abstract] [Full Text] [Related]
29. Aromatase inhibitors for breast cancer.
Briest S; Davidson NE
Rev Endocr Metab Disord; 2007 Sep; 8(3):215-28. PubMed ID: 17486453
[TBL] [Abstract][Full Text] [Related]
30. Switching to aromatase inhibitors in early breast cancer.
Boccardo F; Rubagotti A
Lancet; 2007 Feb; 369(9561):533-5. PubMed ID: 17307082
[No Abstract] [Full Text] [Related]
31. ATAC trial update.
de Castro G
Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
[No Abstract] [Full Text] [Related]
32. The role of aromatase inhibitor (AI) in the treatment of breast cancer.
Irawan C; Abdulmuthalib
Acta Med Indones; 2005; 37(1):43-8. PubMed ID: 15879638
[No Abstract] [Full Text] [Related]
33. Aromatase inhibitors--a triumph of translational oncology.
Swain SM
N Engl J Med; 2005 Dec; 353(26):2807-9. PubMed ID: 16382068
[No Abstract] [Full Text] [Related]
34. Adjuvant endocrine therapy for postmenopausal women: Type and duration.
Mayer EL; Burstein HJ
Breast; 2015 Nov; 24 Suppl 2():S126-8. PubMed ID: 26279133
[TBL] [Abstract][Full Text] [Related]
35. Can switching treatments improve breast-cancer outcome?
Fricker J
Lancet Oncol; 2006 Jul; 7(7):536. PubMed ID: 16848012
[No Abstract] [Full Text] [Related]
36. Optimal adjuvant endocrine therapy for early breast cancer.
Stuart-Harris R; Davis A
Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
[TBL] [Abstract][Full Text] [Related]
37. [Future endocrine therapy of breast cancer].
Ejlertsen B
Ugeskr Laeger; 2007 Jan; 169(4):296. PubMed ID: 17274921
[No Abstract] [Full Text] [Related]
38. Current developments in hormonal therapy of breast cancer.
Buzdar AU
Clin Breast Cancer; 2004 Sep; 5 Suppl 1():S4-5. PubMed ID: 15347432
[No Abstract] [Full Text] [Related]
39. Aromatase inhibitors versus tamoxifen as adjuvant hormonal therapy for oestrogen sensitive early breast cancer in post-menopausal women: meta-analyses of monotherapy, sequenced therapy and extended therapy.
Josefsson ML; Leinster SJ
Breast; 2010 Apr; 19(2):76-83. PubMed ID: 20096578
[TBL] [Abstract][Full Text] [Related]
40. Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer.
Robinson B; Dijkstra B; Davey V; Tomlinson S; Frampton C
Clin Oncol (R Coll Radiol); 2018 Jan; 30(1):e9-e15. PubMed ID: 29103853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
